Loading clinical trials...
Loading clinical trials...
An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as Evidenced by Changes in Liver Biopsy in Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Conditions
Interventions
ARC-AAT Injection
Locations
4
Canada
Research Site 1
Toronto, Ontario, Canada
Research Site 2
Dublin, Ireland
Research Site 3
Pavia, Italy
Research Site 4
Malmo, Sweden
Start Date
October 1, 2016
Primary Completion Date
November 1, 2016
Completion Date
November 1, 2016
Last Updated
December 18, 2025
NCT00500123
NCT02796937
NCT06186492
NCT03815396
NCT03767829
NCT02001688
Lead Sponsor
Arrowhead Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions